NCT00091689已完成1 期
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 试验地点
- 2
研究概览
简要总结
Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions. The study will also measure blood levels of the drug and examine the potential anti-tumor activity of the cream.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have melanoma cutaneous metastasis or lentigo maligna melanoma unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
- •Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
- •Have a life expectancy of 4 months
- •Have normal organ and bone marrow function
排除标准
- •Need for non-steroidal anti-inflammatory drugs (NSAIDs) during the study
- •Have a body mass index (BMI)> 30 kg/m2
- •Have a history of, or clinical evidence of, myocardial ischemia, congestive heart failure, or myocardial arrhythmias requiring treatment within the past 6 months
- •Have uncontrolled intercurrent or chronic illness, but not limited to, ongoing or active infection such as hepatitis B or C, immune dysfunction such as autoimmune disease, endocrine dysfunction such as hypo- or hyperthyroidism, psychiatric illness such as depression or suicidal tendency or social situations that would limit compliance with study requirements
- •Have a history of disease requiring ongoing steroid treatment
- •Have a history of seizure disorder (other than febrile seizures in childhood)
- •Have a history of clinically significant coagulation or bleeding disorders or abnormalities
- •Are HIV positive. HIV positive subjects are excluded from the study because of possible interactions with the immunomodulatory effects of 852A and because of potential pharmacokinetic interactions associated with combination retroviral therapy.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
AST-021p Study in Advanced Solid TumorsAdvanced CancerNCT04864418Aston Sci. Inc.22
已完成
1 期
A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2MalariaNCT03203421University of Oxford18
已完成
1 期
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult ParticipantsHealthy VolunteerNCT06774313AbbVie73
进行中（未招募）
1 期
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™Malaria,FalciparumNCT06320535University of Oxford36
已完成
1 期
Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve AdultsZika VirusNCT03611946National Institute of Allergy and Infectious Diseases (NIAID)56